Man Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-915,689
| Closed | -$36.8M | – | 2331 |
|
|
2026
Q1 | $36.8M | Buy |
915,689
+771,418
| +535% | +$16.6M | 0.07% | 302 |
|
|
2025
Q4 | $3.62M | Buy |
144,271
+77,069
| +115% | +$1.81M | 0.01% | 1216 |
|
|
2025
Q3 | $1.52M | Buy |
+67,202
| New | +$1.57M | ﹤0.01% | 1523 |
|
|
2025
Q2 | – | Sell |
-1,027,792
| Closed | -$22.5M | – | 2167 |
|
|
2025
Q1 | $22.5M | Buy |
1,027,792
+978,500
| +1,985% | +$27M | 0.06% | 397 |
|
|
2024
Q4 | $1.57M | Buy |
49,292
+32,550
| +194% | +$979K | ﹤0.01% | 1382 |
|
|
2024
Q3 | $483K | Sell |
16,742
-60,487
| -78% | -$2.24M | ﹤0.01% | 1662 |
|
|
2024
Q2 | $2.96M | Buy |
+77,229
| New | +$3.5M | 0.01% | 1216 |
|
|
2023
Q1 | – | Sell |
-105,784
| Closed | -$6.1M | – | 1710 |
|
|
2022
Q4 | $5.47M | Sell |
105,784
-37,601
| -26% | -$1.99M | 0.02% | 797 |
|
|
2022
Q3 | $9.79M | Buy |
+143,385
| New | +$8.48M | 0.05% | 479 |
|
|
2022
Q2 | – | Sell |
-63,852
| Closed | -$2.91M | – | 1320 |
|
|
2022
Q1 | $3.24M | Buy |
+63,852
| New | +$2.82M | 0.01% | 1063 |
|
|
2021
Q4 | – | Sell |
-23,300
| Closed | -$768K | – | 1939 |
|
|
2021
Q3 | $768K | Sell |
23,300
-66,125
| -74% | -$3.72M | ﹤0.01% | 1420 |
|
|
2021
Q2 | $5.65M | Sell |
89,425
-95,649
| -52% | -$4.94M | 0.02% | 829 |
|
|
2021
Q1 | $7.94M | Sell |
185,074
-36,126
| -16% | -$1.71M | 0.03% | 503 |
|
|
2020
Q4 | $12.7M | Sell |
221,200
-26,686
| -11% | -$1.13M | 0.06% | 365 |
|
|
2020
Q3 | $7.48M | Sell |
247,886
-9,460
| -4% | -$283K | 0.03% | 607 |
|
|
2020
Q2 | $8.4M | Buy |
257,346
+244,384
| +1,885% | +$7.85M | 0.04% | 429 |
|
|
2020
Q1 | $347K | Buy |
+12,962
| New | +$460K | ﹤0.01% | 1360 |
|
Other funds holding APLS
Man Group's APLS Position: Q2 2026 in Review
Man Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 915,689 shares — an estimated $36.8M sold.
Man Group first reported a position in APLS in Q1 2020 and held it in 17 quarters. The position peaked at $36.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Man Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Man Group sold 915,689 Apellis Pharmaceuticals shares in Q2 2026, an estimated $36.8M.
- Man Group first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 17 quarters.
- Man Group's Apellis Pharmaceuticals position peaked at $36.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.